Skip to main content

Table 1 Proportion of arrhythmic risk factors in Fabry cohorts

From: Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy

  Fabry disease
Primary prevention
N = 36
Secondary prevention
N = 14
p value
Age (years) 58 ± 12 57 ± 12 0.922
Male gender (n, %) 8 (22) 2 (7) 0.704
MSSI > 20 (n, %) 10 (28) 2 (14) 0.468
LVH (n, %) 32 (89) 12 (86) 1.000
LGE > 3 segments (n, %) 11 (41) 3 (11) 0.115
Elevated troponin (n, %) 7 (19) 4 (29) 0.476
QRS duration > 120 ms (n, %) 21 (58) 7 (50) 0.719